A 52-year-old woman with stage II breast cancer is scheduled for radiotherapy

Last updated: April 7, 2026Bookmark

A 52-year-old woman presents with a 3-month history of a painless lump in her left breast. Biopsy confirms invasive ductal carcinoma, stage II (T2N1M0). She undergoes breast-conserving therapy (lumpectomy with sentinel lymph node biopsy). Post-operatively, she is referred to the oncology clinic where the multidisciplinary team recommends adjuvant radiotherapy to the left breast and regional lymph nodes. She is scheduled for external beam radiotherapy using modern planning techniques.

Q1. What is radiotherapy?

Radiotherapy, also known as radiation therapy, is the use of ionising radiation to destroy cancer cells

Ionising radiation is high-energy radiation that displaces electrons from atoms and molecules. This can be in the form of electromagnetic waves (photons and gamma rays) and particles (neutrons and protons)

A gamma ray is a photon that is emitted spontaneously by a radioactive substance

Q2. Why is radiotherapy indicated for this patient?

Radiotherapy is indicated after breast-conserving surgery to reduce the risk of local recurrence

It also treats potential microscopic residual disease in the breast and regional lymph nodes

The overall survival is also improved with adjuvant radiotherapy

Q3. What are the main techniques of radiotherapy?
TechniqueDescriptionExamples
External beam radiotherapy (EBRT)This is the most common method. Radiation is delivered from a source outside the bodyConventional 2D radiotherapy, 3D conformal radiotherapy (3D-CRT), Intensity-modulated radiotherapy, volumetric modulated radiotherapy (VMAT), Image-guided radiotherapy (IGRT), 4D radiotherapy, stereotactic radiotherapy (SRS/SBRT), proton beam therapy
Internal radiotherapy (Brachytherapy)A radioactive source is placed inside/next to the tumour. This delivers high local radiation doses with minimal exposure to surrounding tissue.Intracavitary (cervix, uterus), interstitial (prostate, breast)
Systemic radiotherapyRadioactive isotopes are administered systemically either through the oral or intravenous routeRadioactive iodine (I-131 for thyroid cancer), strontium-89 or samarium-153 (for bone metastases), lutetium-177 dotatate (for neuroendocrine tumours)

Q4. What is the meaning of fractionation of radiotherapy?

Fractionation refers to dividing a treatment over a period of time

Fractionation results in shrinking of the tumour mass over time, making the inner, previously anoxic cells more sensitive to radiation

Q5. What is the mechanism of action of radiotherapy?

Ionising radiation damages DNA and cellular structures both directly and indirectly

Direct effect is through inducing single and double-stranded breaks in DNA

Indirect effects are through generating reactive oxygen species (ROS), which damage DNA, proteins and membranes

The effect of radiotherapy is based on the 5 R’s (radiobiology of radiotherapy):

Repair: cancer cells have defective DNA repair mechanisms, making them more sensitive to ionising radiation

Redistribution: Fractionation allows cells to move from a radio-resistant phase to a radiosensitive phase (S/M/G2). Redistributes partially synchronised cells to the same part of the cell cycle, causing G2/M block

Reoxygenation: The presence of oxygen prevents normal repair of single and double-stranded DNA breaks. Hypoxic cells limit the curability of cancer.

Repopulation: Killing tumour and normal cells allows both of them to repopulate, but normal cells repair DNA breaks faster than tumour cells, particularly because most of the tumour cells will now be re-oxgenated.

Radiosensitivity: Targeting tissues that are more/less radiosensitive

Cells are most sensitive to ionising radiation in the G2/M phase, while they are relatively resistant in the S phase

Cancer cells are rapidly dividing and have defective DNA repair mechanisms. This makes them more sensitive to ionising radiation than non-cancerous cells.

The outcome is:

Mitotic catastrophe (cells are unable to divide)

Senescence (permanent growth arrest)

Apoptosis or necrosis

Effects of ionising radiation
Q6. Which tumours are most sensitive to radiotherapy?
CategoryTumors
Most radiosensitiveLymphoma, germinomas, small cell lung cancer, medulloblastoma, Ewing sarcoma, neuroblastoma, Wilms tumour
Moderately radiosensitiveSquamous cell carcinoma, transitional cell carcinoma of the bladder, breast cancer, prostate cancer
RadioresistantMelanoma, renal cell carcinoma, sarcoma (except Ewing sarcoma), glioblastoma multiforme
Q7. What are the clinical applications of radiation therapy?
Clinical applicationDescriptionExamples
Curative therapyUsed for localised cancers where a cure is possibleHead and neck cancer, cervical cancer (via brachytherapy), Hodgkin’s lymphoma, prostate cancer,
Adjuvant therapyUsed after surgery to reduce recurrenceBreast cancer, brain tumours
Neoadjuvant therapyUsed before surgery to reduce the size of tumoursRectal cancer, esophageal cancer
Palliative therapyUsed for symptom relief in advanced diseaseFor pain in bone metastases, symptomatic brain metastases, lung cancer, bleeding tumours, and spinal cord compression
Prophylactic therapyUsed to prevent metastasis in sanctuary sitesProphylactic cranial irradiation in small cell lung cancer
Q8. What are the steps of radiation therapy, including planning?

Consultation and Decision/ preauthorisation and dose prescription

Indication assessed. Clinician fills intent form, consent obtained. Patient file is opened, and dose recorded

Simulation/ positioning and immobilisation

CT/MRI planning scans performed in treatment position

Align the patient to the room coordinate systems

Sedate patients who cannot follow commands, e.g. children

Target Delineation/ contouring

Gross Tumour Volume (GTV)

Clinical Target Volume (CTV)

Planning Target Volume (PTV)

Organs at Risk (OARs) are outlined.

Treatment Planning

Computerised planning system calculates optimal beam arrangement, dose, and shielding

Dose Prescription

Typically measured in Gray (Gy), fractionated (e.g., 2 Gy/day × 25 fractions).

Verification & Quality Assurance

Portal imaging / cone-beam CT to verify accuracy.

Treatment Delivery

Radiation administered as per plan.

Follow-up & Assessment

Monitor response and manage side effects.

In summary: Pateint positioning and immobilisation→ volumetric data acquisition→ image transfer to the TPS→ Target volume delineation→ 3D model→ forward or inverse planning→ dose distribution→ treatment QA→ Treatment delivery

Q9. What are the side effects of radiation therapy?
SystemExamples
ConstitutionalFatigue, malaise, anorexia, nausea
Skin and connective tissueErythema, hyperpigmentation, desquamation, radiation dermatitis, atrophy, telangiectasia, fibrosis, poor wound healing, secondary skin cancer
HaematologicAnaemia, leukopaenia, thrombocytopaenia
GastrointestinalMucositis, esophagitis, nausea, vomiting, diarrhoea, abdominal cramps, strictures, ulceration, fistulae, radiation enteritis/proctitis, malabsorptions
RespiratoryRadiation pneumonitis, pulmonary fibrosis, restrictive lung disease
CardiovascularPericarditis, restrictive cardiomyopathy
NeurologicalCerebral edema, somnolence syndrome, radiation myelopathy, cognitive impairment, memory loss, necrosis of brain tissue
EndocrineHypothyroidism (neck), hypopituitarism (cranial), growth retardiation (skeletal and endocrine), infertility (gonads)
GenitourinaryCystitis, dysuria, frequency, hematuria, contracted bladder, fistula formation, and infertility
OphtlamologicConjunctivitis, keratitis, cataracts, retinopathy, optic neuropathy
Head and neckOtitis externa, serous otitis, sensorineural hearing loss, xerostomia, mucositis, dental caries, osteoradionecrosis (mandible)

Reference Intervals
Biochemistry
ACTHP: <80 ng/L
ALTP: 5–35 U/L
AlbuminP: 35–50 g/L
AldosteroneP: 100–500 pmol/L
Alk. phosphataseP: 30–130 U/L
α-AmylaseP: 0–180 IU/dL
α-FetoproteinS: <10 kU/L
Angiotensin IIP: 5–35 pmol/L
ADHP: 0.9–4.6 pmol/L
ASTP: 5–35 U/L
BicarbonateP: 24–30 mmol/L
BilirubinP: 3–17 μmol/L
BNPP: <50 ng/L
CRPP: <10 mg/L
CalcitoninP: <0.1 mcg/L
Calcium (ionized)P: 1.0–1.25 mmol/L
Calcium (total)P: 2.12–2.60 mmol/L
ChlorideP: 95–105 mmol/L
CholesterolP: <5.0 mmol/L
VLDLP: 0.128–0.645 mmol/L
LDLP: <2.0 mmol/L
HDLP: 0.9–1.93 mmol/L
Cortisol AMP: 450–700 nmol/L
Cortisol MidnightP: 80–280 nmol/L
CK ♂P: 25–195 U/L
CK ♀P: 25–170 U/L
CreatinineP: 70–100 μmol/L
FerritinP: 12–200 mcg/L
FolateS: 2.1 mcg/L
FSHP: 2–8 U/L ♂; >25 menopause
GGT ♂P: 11–51 U/L
GGT ♀P: 7–33 U/L
Glucose (fasting)P: 3.5–5.5 mmol/L
Growth hormoneP: <20 mu/L
HbA1C (DCCT)B: 4–6%
HbA1C (IFCC)B: 20–42 mmol/mol
Iron ♂S: 14–31 μmol/L
Iron ♀S: 11–30 μmol/L
Lactate (venous)P: 0.6–2.4 mmol/L
Lactate (arterial)P: 0.6–1.8 mmol/L
LDHP: 70–250 U/L
LHP: 3–16 U/L
MagnesiumP: 0.75–1.05 mmol/L
OsmolalityP: 278–305 mosmol/kg
PTHP: 0.8–8.5 pmol/L
PotassiumP: 3.5–5.3 mmol/L
Prolactin ♂P: <450 U/L
Prolactin ♀P: <600 U/L
PSAP: 0–4 mcg/mL
Protein (total)P: 60–80 g/L
Red cell folateB: 0.36–1.44 μmol/L
Renin (erect)P: 2.8–4.5 pmol/mL/h
Renin (recumbent)P: 1.1–2.7 pmol/mL/h
SodiumP: 135–145 mmol/L
TBGP: 7–17 mg/L
TSHP: 0.5–4.2 mU/L
T4P: 70–140 nmol/L
Free T4P: 9–22 pmol/L
TIBCS: 54–75 μmol/L
TriglyceridesP: 0.50–2.3 mmol/L
T3P: 1.2–3.0 nmol/L
Troponin TP: <0.1 mcg/L
Urate ♂P: 210–480 μmol/L
Urate ♀P: 150–390 μmol/L
UreaP: 2.5–6.7 mmol/L
Vitamin B12S: 0.13–0.68 nmol/L
Vitamin DS: 50 nmol/L
Arterial Blood Gases
pH7.35–7.45
PaCO₂4.7–6.0 kPa
PaO₂>10.6 kPa
Base excess±2 mmol/L
Urine
Cortisol (free)<280 nmol/24h
Hydroxyindole acetic acid16–73 μmol/24h
Hydroxymethylmandelic acid16–48 μmol/24h
Metanephrines0.03–0.69 μmol/mmol cr.
Osmolality350–1000 mosmol/kg
17-Oxogenic steroids ♂28–30 μmol/24h
17-Oxogenic steroids ♀21–66 μmol/24h
17-Oxosteroids ♂17–76 μmol/24h
17-Oxosteroids ♀14–59 μmol/24h
Phosphate (inorganic)15–50 mmol/24h
Potassium14–120 mmol/24h
Protein<150 mg/24h
Protein/creatinine ratio<3 mg/mmol
Sodium100–250 mmol/24h
Haematology
WCC4.0–11.0 ×10⁹/L
RBC ♂4.5–6.5 ×10¹²/L
RBC ♀3.9–5.6 ×10¹²/L
Hb ♂130–180 g/L
Hb ♀115–160 g/L
PCV ♂0.4–0.54 L/L
PCV ♀0.37–0.47 L/L
MCV76–96 fL
MCH27–32 pg
MCHC300–360 g/L
RDW11.6–14.6%
Neutrophils2.0–7.5 ×10⁹/L (40–75%)
Lymphocytes1.0–4.5 ×10⁹/L (20–45%)
Eosinophils0.04–0.44 ×10⁹/L (1–6%)
Basophils0–0.10 ×10⁹/L (0–1%)
Monocytes0.2–0.8 ×10⁹/L (2–10%)
Platelets150–400 ×10⁹/L
Reticulocytes0.8–2.0% / 25–100 ×10⁹/L
Prothrombin time10–14 s
APTT35–45 s
Paediatric
Pulse Rate (bpm)
Neonate140–160
Infant <1yr120–140
1–5 years110–130
5–12 years80–120
>12 years70–100
Respiratory Rate (tachypnoea)
0–2 months≥60/min
2–12 months≥50/min
1–5 years≥40/min
>5 years≥30/min
Blood Pressure (mmHg)
Term65/45
1 year75/50
4 years85/60
8 years95/65
10 years100/70
Weight Formulas
3–12 months(a + 9)/2 kg
1–6 years2a + 8 kg
>6 years(7a − 5)/2 kg
Haemoglobin (g/dL)
Term newborn13–20
1 month11–18
2 months10–15
1–2 years10–13
>2 years11–14
MUAC (6 months–5 years)
Obese>17.5 cm
Normal13.5–17.4 cm
At risk12.5–13.4 cm
Moderate malnutrition11.5–12.4 cm
Severe malnutrition<11.5 cm
Developmental Milestones
Social smile1.5 months
Head control4 months
Sits unsupported7 months
Crawls10 months
Stands unsupported10–12 months
Walks12–13 months
Talks18 months
CSF WBC (/mm³)
Term newborn0–25
>2 weeks0–5
Calculator

Leave a Reply

A moment of your time
Step 1 of 2

You are the reason this exists. Got 60 seconds? Help us improve Hyperexcision for every medical student who uses it.

The Hyperexcision Team